ADITXT INC (ADTX) 0.8543 -0.03 (-3.73%)
0.8543 -0.03 (-3.73%)
US0070255056 - Common Stock - After market: 0.84 -0.01 (-1.67%)
Fundamental Rating
Taking everything into account, ADTX scores 2 out of 10 in our fundamental rating. ADTX was compared to 639 industry peers in the Biotechnology industry. ADTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ADTX is valued expensive at the moment.
Note: ADTX has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
ADTX has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ADTX.
VS Industry
Valuation
Valuation Rating
When comparing the current price to the book value of ADTX, it is valued rather cheaply. It is trading at 0.29 times its book value.
When comparing the price book ratio of ADTX to the average industry price book ratio of 1.53, ADTX is valued rather cheaply. ADTX is also cheaper than 93% of the companies listed in the same industry.
ADTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Price/Book (0.29) VS Industry: 93% outperformed.
1,769.21
0.10
Growth
Growth Rating
ADTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.38%, which is quite impressive.
ADTX is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 25.92% yearly.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 60.38% | 95.95% | 40.68% | 25.92% | N/A |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
ADTX has a Current Ratio of 2.89. This indicates that ADTX is financially healthy and has no problem in meeting its short term obligations.
ADTX has a Quick Ratio of 2.56. This indicates that ADTX is financially healthy and has no problem in meeting its short term obligations.
The Debt to Equity ratio of ADTX is in line with the industry averages.
When comparing the Current Ratio of ADTX to the average industry Current Ratio of 5.92, ADTX is less able to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of ADTX to the average industry Current Ratio of 5.91, ADTX is less able to pay its short term obligations than its industry peers.
Based on the Altman-Z score of -12.53, we must say that ADTX is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of ADTX to the average industry Altman-Z score of -0.54, ADTX is less financially healthy than its industry peers. 86% of its industry peers have a better Altman-Z score.
ADTX has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ADTX.
VS Industry
Debt/Equity (0) VS Industry: 43% outperformed.
13.13
0.00
Quick Ratio (2.56) VS Industry: 22% outperformed.
0.04
84.53
Current Ratio (2.89) VS Industry: 25% outperformed.
0.08
85.09
Altman-Z (-12.53) VS Industry: 14% outperformed.
-94.42
417.58
Dividend
Dividend Rating
No dividends for ADTX!.
ADITXT INC0.8543
NASDAQ:ADTX (3/24/2023, 8:14:11 PM)-0.03 (-3.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change-97.43%
Ins Owners0%
Ins Owner Change0%
Market Cap3.67M
Analysts80
Price Target4.08 (377.58%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)-167.16%
Min EPS beat(2)-215.86%
Max EPS beat(2)-118.46%
EPS beat(4)N/A
Avg EPS beat(4)-197.81%
Min EPS beat(4)-232.14%
Max EPS beat(4)-118.46%
Revenue beat(2)N/A
Avg Revenue beat(2)-49.95%
Min Revenue beat(2)-97.98%
Max Revenue beat(2)-1.92%
Revenue beat(4)N/A
Avg Revenue beat(4)-65.95%
Min Revenue beat(4)-97.98%
Max Revenue beat(4)-1.92%
PT rev (1m)0%
PT rev (3m)-85.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-189.45%
EPS NY rev (3m)-189.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-23.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.29 | ||
| P/tB | 0.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-34.27
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-5.76
FCFYN/A
OCF(TTM)-5.67
OCFYN/A
SpS0.2
BVpS2.96
TBVpS2.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 20.93% |
ROICexgc(3y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc(3y)N/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 77.61% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.56 | ||
| Altman-Z | -12.53 |
F-Score3
WACC8.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y60.38%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q73.65%
EPS Next Y95.95%
EPS Next 2Y40.68%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue growth 1YN/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-82.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-479.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-492.78%
OCF growth 3YN/A
OCF growth 5YN/A
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA